BioCardia Inc 2026年季度报告

FORM 10-Q (Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934Commission file number: 001-38999 BioCardia, Inc. (Exact name of registrant as specified in its charter) 320 Soquel WaySunnyvale, California 94085(Address of principal executive offices including zip code) (650) 226-0120(Registrant’s telephone number, including area code) N/A(Former name, former address and former fiscal year, if changed since last report) Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject tosuch filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, oran emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerginggrowth company” in Rule 12b-2 of the Exchange Act. Largeacceleratedfiler☐ Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ Securities registered pursuant to Section 12(b) of the Act: Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. There were 11,374,724shares of the registrant’s Common Stock issued and outstanding as of May 13, 2026. Part I.FINANCIAL INFORMATION Item 1.Unaudited Condensed Consolidated Financial Statements1Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 20251Condensed Consolidated Statements of Operations for the three months ended March 31, 2026 and 20252Condensed Consolidated Statements of Stockholders’Equity (Deficit) for the three months ended March 31, 2026 and 20253Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 20254Notes to Unaudited Condensed Consolidated Financial Statements5Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations11Item 3.Quantitative and Qualitative Disclosures About Market Risk17Item 4.Controls and Procedures18 Part II.OTHER INFORMATION19 Item 1.Legal Proceedings19Item 1A. Risk Factors19Item 2.Unregistered Sales of Equity Securities and Use of Proceeds19Item 3.Defaults Upon Senior Securities19Item 4.Mine Safety Disclosures19Item 5.Other Information19Item 6.Exhibits20 EXHIBIT INDEXSIGNATURES 2021 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q, or report, contains forward-looking statements within the meaning of the U.S. federal securities laws thatinvolve risks and uncertainties. Certain statements contained in this report are not purely historical including, without limitation, statementsregarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the development of our celltherapy systems, our clinical trials, and our business development initiatives, (ii) a projection of income (including income/loss), earnings(including earnings/loss) per share, capital expenditures, dividends, capital structure or resources or other financial items, (iii) our need andability to raise additional capital, (iv) our future financial performance, including any such statement contained in a discussion and analysis offinancial condition by management or in the results of operations included pursuant to the rules and regulations of the SEC, (v) our ability todevelop and advance current product candidates and programs and execute on our corporate strategy and (vi) the assumptions underlying orrelating to any statement described in points (i)–(v) above. These statements include those discussed in Item 2, Management’s Discussion andAnalysis of Financial Condition and Results of Operations, including“Critical Accounting Policies and Estimates,”“Results of Operations,”“Liquidity and Capital Resources,”and“Future Funding Requirements,”and elsewhere in this report. In this report, the words“may,”“could,”“would,”“migh